(NASDAQ: VRDN) Viridian Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.
Viridian Therapeutics's earnings in 2024 is -$228,055,000.On average, 8 Wall Street analysts forecast VRDN's earnings for 2024 to be -$253,566,314, with the lowest VRDN earnings forecast at -$264,504,269, and the highest VRDN earnings forecast at -$235,753,805. On average, 7 Wall Street analysts forecast VRDN's earnings for 2025 to be -$274,273,038, with the lowest VRDN earnings forecast at -$343,727,770, and the highest VRDN earnings forecast at -$235,753,805.
In 2026, VRDN is forecast to generate -$257,476,378 in earnings, with the lowest earnings forecast at -$357,783,552 and the highest earnings forecast at -$169,308,288.